Back to top
more

Regeneron Pharmaceuticals (REGN)

(Delayed Data from NSDQ)

$571.54 USD

571.54
1,357,988

+12.67 (2.27%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $573.98 +2.44 (0.43%) 6:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for PBE

Zacks Equity Research

Alnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y

by Zacks Equity Research

Alnylam (ALNY) reports better-than-expected first-quarter 2024 results as both earnings and revenues beat estimates, primarily driven by strong Amvuttra sales.

Zacks Equity Research

Ultragenyx (RARE) Q1 Loss Wider Than Expected, Revenues Rise Y/Y

by Zacks Equity Research

Ultragenyx (RARE) reports dismal first-quarter 2024 results, missing both earnings and revenue estimates, despite the year-over-year increase of Crysvita and Dojolvi sales.

Zacks Equity Research

Regeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales

by Zacks Equity Research

Regeneron (REGN) reports Q1 results, wherein both the top and bottom lines miss estimates due to lower Eylea sales. Shares down.

Zacks Equity Research

Regeneron (REGN) Reports Q1 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?

by Zacks Equity Research

Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.

Zacks Equity Research

Should You Consider Regeneron (REGN) Ahead of Q1 Earnings?

by Zacks Equity Research

An increase in profits from Dupixent and further uptake of Eylea HD are likely to have aided Regeneron (REGN) in partially offsetting the decline in Eylea sales.

Zacks Equity Research

Down -8.24% in 4 Weeks, Here's Why Regeneron (REGN) Looks Ripe for a Turnaround

by Zacks Equity Research

Regeneron (REGN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks Equity Research

Countdown to Regeneron (REGN) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS

by Zacks Equity Research

Evaluate the expected performance of Regeneron (REGN) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Zacks Equity Research

EXEL vs. REGN: Which Stock Is the Better Value Option?

by Zacks Equity Research

EXEL vs. REGN: Which Stock Is the Better Value Option?

Zacks Equity Research

Intellia (NTLA) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

On Intellia's (NTLA) first-quarter 2024 earnings call, investors' focus is likely to be on the progress of its pipeline of genome-editing candidates.

Zacks Equity Research

Sanofi (SNY) Q1 Earnings In Line, Sales Miss Estimates, Stock Up

by Zacks Equity Research

Sanofi (SNY) posts first-quarter 2024 results and maintains the earnings growth guidance for the year.

Zacks Equity Research

Regeneron (REGN) Reports Next Week: What You Should Expect

by Zacks Equity Research

Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

The Zacks Analyst Blog Highlights Danaher, Regeneron Pharmaceuticals, Palo Alto Networks, Workday and American Electric Power

by Zacks Equity Research

Danaher, Regeneron Pharmaceuticals, Palo Alto Networks, Workday and American Electric Power are part of the Zacks top Analyst Blog.

Mark Vickery headshot

Top Stock Reports for Danaher, Regeneron Pharmaceuticals & Palo Alto Networks

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Danaher Corporation (DHR), Regeneron Pharmaceuticals, Inc. (REGN) and Palo Alto Networks, Inc. (PANW).

Zacks Equity Research

Roche (RHHBY) Q1 Hit by Currency Headwinds, Lower COVID-19 Sales

by Zacks Equity Research

Roche's (RHHBY) performance in first-quarter 2024 is pretty ho-hum as COVID-19-test sales continue to decline. The top line suffers due to the appreciation of the Swiss franc against most currencies.

Zacks Equity Research

Agenus (AGEN) Soars 6.8%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Agenus (AGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks Equity Research

Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success

by Zacks Equity Research

Regeneron (REGN) and Sage Therapeutics (SAGE) are in focus on regulatory and pipeline updates.

Zacks Equity Research

2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's Why

by Zacks Equity Research

The FDA's recent nod to 2seventy bio's (TSVT) Abecma in earlier lines of treatment for relapsed/refractory multiple myeloma is a positive. Also, the R&D asset divestiture to Regeneron is saving costs.

Zacks Equity Research

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Zacks Equity Research

Why Regeneron (REGN) Could Beat Earnings Estimates Again

by Zacks Equity Research

Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Regeneron (REGN) Accused of Fraudulent Practices Related to Eylea

by Zacks Equity Research

The U.S. Department of Justice files a complaint against Regeneron (REGN), alleging fraudulent drug pricing practices related to its lead drug, Eylea.

Zacks Equity Research

EXEL or REGN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

EXEL vs. REGN: Which Stock Is the Better Value Option?

Zacks Equity Research

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for IBB

Zacks Equity Research

Kodiak (KOD) Counts on Tarcocimab Program Despite Setbacks

by Zacks Equity Research

Kodiak (KOD) initiates a phase III study evaluating tarcocimab in diabetic retinopathy, which is expected to serve as the basis for a regulatory filing for three eye disease indications.